Analysis of Response to Pembrolizumab and Lenvatinib in pMMR Endometrial Cancers: A Retrospective Cohort Study.

In this real-world cohort of pMMR endometrial cancer patients treated with PL, the median PFS of 4.2 months was shorter than the 6.6 months reported in Study 309-KEYNOTE-775. Patients in the IO group had significantly longer PFS when compared with the PL group, though patients in the IO group had fewer prior lines of therapy. Small cohort sizes are a significant limitation of this analysis. Further study is needed to confirm whether the analyzed variables maintain potential significance in larger matched cohorts.